Whitehawk Therapeutics (WHWK) Other financing activities (2016 - 2026)
Whitehawk Therapeutics (WHWK) posted quarterly Other financing activities of $2000.0 for Q3 2025, down 33.33% quarter-over-quarter from $3000.0 in Q2 2025.
Powered by 
Analysis
Whitehawk Therapeutics (WHWK) Other financing activities (2016 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Other financing activities for 8 consecutive years, with $2000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other financing activities changed N/A year-over-year to $2000.0; the TTM figure through Mar 2026 stood at $5000.0 (down 76.19% YoY), while the FY2025 annual figure was $26000.0, changed N/A from the prior year.
- Other financing activities fell to $2000.0 in Q3 2025 per WHWK's latest filing, from $3000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $745000.0 in Q3 2021 and bottomed at -$745000.0 in Q4 2021.
- Historically, Other financing activities has averaged $31812.5 across 5 years, with a median of $35000.0 in 2023.
- On a YoY basis, Other financing activities climbed as much as 293.51% in 2022 and fell as far as 151.01% in 2022.
- Whitehawk Therapeutics' Other financing activities stood at -$745000.0 in 2021, then soared by 143.36% to $323000.0 in 2022, then slumped by 141.49% to -$134000.0 in 2023, then increased by 29.85% to -$94000.0 in 2024, then surged by 102.13% to $2000.0 in 2025.
- Business Quant data shows WHWK's Other financing activities at $2000.0 in Q3 2025, $3000.0 in Q2 2025, and $21000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Whitehawk Therapeutics | 377.13 Mn | 377.13 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 90,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Mar 31, 2025 | 21,000.00 |
| Dec 31, 2024 | 52,000.00 |
| Jun 30, 2024 | 84,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Dec 31, 2023 | 114,000.00 |
| Jun 30, 2023 | 286,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 5,000.00 |
| Sep 30, 2022 | 16,000.00 |
| Jun 30, 2022 | 136,000.00 |
| Mar 31, 2022 | 244,000.00 |
| Dec 31, 2021 | 88,000.00 |
| Sep 30, 2021 | 745,000.00 |
| Jun 30, 2021 | -70,279.00 |
| Mar 31, 2021 | 70,279.00 |
| Dec 31, 2018 | 76.00 |
| Sep 30, 2018 | 53,104.00 |
| Jun 30, 2018 | 1,660.00 |